Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service
about
Vismodegib hedgehog-signaling inhibition and treatment of basal cell carcinomas as well as keratocystic odontogenic tumors in Gorlin syndromeBehaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competenceTumors of the neural crest: Common themes in development and cancerAlternative splicing of the neurofibromatosis type I pre-mRNAA RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressorBasal cell carcinoma - molecular biology and potential new therapiesPhase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.Discovery of Rare Mutations in Autism: Elucidating Neurodevelopmental MechanismsPlexiform Neurofibroma: A Case Report.Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosisPrimary culture of human Schwann and schwannoma cells: improved and simplified protocol.Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2.mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.Optimizing biologically targeted clinical trials for neurofibromatosis.Risk of benign tumours of nervous system, and of malignant neoplasms, in people with neurofibromatosis: population-based record-linkage studyPhase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features.Genetic predisposition to peripheral nerve neoplasia: diagnostic criteria and pathogenesis of neurofibromatoses, Carney complex, and related syndromesMalignant peripheral nerve sheath tumours in inherited diseaseMortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989.Microdeletion del(22)(q12.2) encompassing the facial development-associated gene, MN1 (meningioma 1) in a child with Pierre-Robin sequence (including cleft palate) and neurofibromatosis 2 (NF2): a case report and review of the literature.Angiosarcoma arising in schwannoma of cerebellopontine angle and later associating with meningioma in a patient with neurofibromatosis type 2.Characterizing the microstructural basis of "unidentified bright objects" in neurofibromatosis type 1: A combined in vivo multicomponent T2 relaxation and multi-shell diffusion MRI analysisLongitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2.Motor problems in children with neurofibromatosis type 1.Neurofibromatosis type 1 is not associated with subarachnoid haemorrhage.Bone mineral density in children and young adults with neurofibromatosis type 1Basal cell carcinomas in gorlin syndrome: a review of 202 patients.Novel PTCH1 mutations in patients with keratocystic odontogenic tumors screened for nevoid basal cell carcinoma (NBCC) syndrome.Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.Genetic and functional studies implicate synaptic overgrowth and ring gland cAMP/PKA signaling defects in the Drosophila melanogaster neurofibromatosis-1 growth deficiency.Neurofibromatosis-related tumors: emerging biology and therapies.Early-Onset Breast Cancer in a Family with Neurofibromatosis Type 1 Associated with a Germline Mutation in BRCA1Common variants modify the age of onset for basal cell carcinomas in Gorlin syndrome.Recent developments in brain tumor predisposing syndromes.The NFTI-QOL: A Disease-Specific Quality of Life Questionnaire for Neurofibromatosis 2.Association between Neurofibromatosis Type 1 and Breast Cancer: A Report of Two Cases with a Review of the LiteratureBehavioral and cognitive outcomes for clinical trials in children with neurofibromatosis type 1A randomized placebo-controlled lovastatin trial for neurobehavioral function in neurofibromatosis I.Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations.
P2860
Q26782853-D97CA130-893C-44C0-82C4-A9B62D6C3373Q26862596-6A35417F-C339-4C50-9CFF-CA48B5392620Q26864763-1F5C5E22-487D-4FE8-AA1A-6C37AD3C9BDFQ26865241-E4490093-E726-4F01-867A-739A52CA3917Q27003534-44F2C1EA-D7B9-4B67-AE46-E713B8AE3544Q27006913-F3141627-31F9-4A91-B994-844B45FD66A8Q27853117-BD5AC405-0498-4F96-87ED-8BC51FBB0A6FQ28087577-F8BAEEF9-1855-46B7-9261-4E0EB81AE204Q30277357-12665B6E-C694-4E9C-97BC-360F87B21E65Q30357776-0068EAFC-A8B1-4251-8D33-D98FDE82F2ADQ30403742-E2A0C4E5-2D26-4E3A-BDD6-1C38B19BB0F1Q30405514-41006FAA-3DDA-41F9-9AE2-2287129FFE00Q30415483-7D59B8FC-9E7E-4E33-9A0D-8E38F3AFD257Q30438898-47F960EC-EEE3-4A91-8650-B394C588959DQ30444375-068F9076-D977-4D2B-BEBE-71B914E27BABQ30450038-C2C60C47-1077-4392-AFF5-C91792E0CD4BQ30451619-069CCAF1-53F4-4763-90E6-5223109D6E75Q30454537-405F3E7C-06E2-4F61-A482-B97EAF9AD7D8Q30460786-6EDDC1A2-B39A-4D8E-9D0F-F7DC57A579EDQ30461472-3AD3BDA5-87C7-4721-B46C-FBB5C3DC0AF8Q30467373-EA3E3BEC-CE1F-4599-BB1F-0EA19DA367C3Q30771588-9091AD1E-06B9-4EF6-820E-5D7953AB0669Q30831641-F57919B9-C252-4130-97D3-CA0150A1B909Q33561323-435A0CE4-5BF8-4408-A400-E40F8DB94E46Q33706190-4574CD17-90D8-4730-8FDA-AA2D1FD646D4Q33757823-E2568681-7CA8-4A83-98DB-B4CA8AFB4143Q34045437-347F5058-8167-4155-94A3-58D7B995F38DQ34389057-D57E8441-470D-47EF-9A1A-EF2C75808A5DQ34405646-8DA9478B-0470-43A1-B556-5D4AC7579770Q34980977-6A850114-B2DB-4CCE-B678-800D07E639D2Q35053088-27628427-84AF-4AA3-8B37-8758679E4840Q35218073-D7CA9824-4D84-4AC6-83A3-7C8ED3CCFFA4Q35237240-5DC7BDAC-D224-4CC1-BC84-3E378A44E388Q35477995-7D933F4F-3A9D-4675-B539-E9286536EC5FQ35860402-DA4D007F-85EF-46AE-BA9E-558E2553C251Q36180442-8753EEBA-3F91-4A14-852F-50F656B12C15Q36271890-C5873FCE-ADC8-47ED-A64F-086ABF4EDFD2Q36516773-8F62BF32-F127-43BA-8EFD-EC555D82A95AQ36759465-729C0C41-FD1F-4043-8428-158A0D400E74Q36771546-7FBBC9A3-F245-4335-95DD-29CAB3E04AF5
P2860
Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service
description
article
@en
im Februar 2010 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2010
@uk
name
Birth incidence and prevalence ...... amily genetic register service
@en
Birth incidence and prevalence ...... amily genetic register service
@nl
type
label
Birth incidence and prevalence ...... amily genetic register service
@en
Birth incidence and prevalence ...... amily genetic register service
@nl
prefLabel
Birth incidence and prevalence ...... amily genetic register service
@en
Birth incidence and prevalence ...... amily genetic register service
@nl
P2093
P2860
P356
P1476
Birth incidence and prevalence ...... amily genetic register service
@en
P2093
P2860
P304
P356
10.1002/AJMG.A.33139
P407
P50
P577
2010-02-01T00:00:00Z